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Infections caused by anaerobic bacteria have been 
refractory to therapy by fluoroquinolones commonly 
used in the last decade [l]. In contrast, newer 
(trovafloxacin) and investigational (BAY 12-8039, SB- 
265805 or LB20304, gatifloxacin, clinafloxacin) fluoro- 
quinolones possess greater activity against these species, 
enabling clinical use [2,3]. Gatifloxacin, formerly AM- 
1155 or CG5501, is a new 8-methoxy-fluoroquinolone 
with a wide spectrum of activity against aerobic Gram- 
positive cocci and Gram-negative bacilli [4-71, that also 
has high bioavailability that could justify a susceptibility 
breakpoint of 5 2  mg/L [8]. In this report, the results 
of testing gatifloxacin against anaerobic bacteria are 
summarized, as well as comparisons of in vitro results 
from three other agents and the Etest (AB Biodisk, 
Solna, Sweden) method. 
A set of Gram-positive and Gram-negative 
anaerobic bacteria (Table 1) included 200 clinical strains 
that were isolated from recent patient infections at the 
University of Iowa Hospitals and Clinics (Iowa City, 
IA) plus two quality control (QC) strains (Bacteroides 
fragilis ATCC 25285 and Bacteroides thetaiotaomicron 
ATCC 29741). The 164 Gram-negative strains evalu- 
ated consisted of four genera (Bacteroides, Fusobacterium, 
Prevotella, and Killonella), and 103 of these strains 
were Bacteroides fragilis. The 38 Gram-positive isolates 
included representative strains from five genera 
(Clostridium, Peptostreptococcus, Propionibacterium, Bijido- 
bacterium, and Eubacteriurn; see Table 2). All bacterial 
isolates were maintained at  -70°C until processed. 
Reagent-grade gatifloxacin powder was supplied 
by Bristol-Myers Squibb (Princeton, NJ). Etest strips 
containing the following antimicrobial agents were 
obtained from AB Biodisk: clindamycin, gatifloxacin, 
metronidazole, and trovafloxacin. Agar dilution sus- 
ceptibility testing was performed according to the 
methods described in the National Committee for 
Clinical Laboratory Standards (NCCLS) document 
Mll-A3 [9]. These standardized tests require the use of 
Brucella blood agar supplemented with 5% sheep blood 
(PML Microbiologics, Wilsonville, OR, USA) and a 
lo5 CFU/spot initial inoculum. Incubation was for 
48 h under anaerobic conditions. The Etest suscepti- 
bility testing was performed according to the 
instructions found in the manufacturer’s package insert 
[lo]. In brief, the procedure required that an inoculum 
equal to a 1 McFarland turbidity standard be plated on 
a 150-mm Brucella blood agar plate (Remel, Lenexa, 
KS, USA), on which four Etest strips (clindamycin, 
gatifloxacin, metronidazole, trovafloxacin) were placed. 
After incubation for 48 h under anaerobic atmosphere, 
endpoints for Etest MIC susceptibility testing were 
determined. 
The gatifloxacin MIC determined by agar dilution 
and Etest for the Q C  strains ranged from 0.19 to 1 
mg/L for Bacteroidesfragilis, and from 1 to 4 mg/L for 
Bacteroides thetaiotaomicron. Since no NCCLS-approved 
QC limits for the cited strains when testing gatifloxacin 
are available, Enterococcus faecalis ATCC 29212 and 
Staphylococcus aureirs ATCC 29213 were also tested. All 
MIC values obtained with these two Q C  strains were 
within the suggested control ranges published in the 
Etest package insert for gatifloxacin. All other drugs 
evaluated had MIC values that were consistently within 
the suggested range guidelines published by the 
NCCLS [9]. Strains observed to be resistant to metro- 
nidazole were tested again on three occasions by the 
reference agar dilution and Etest methods to avoid 
false-resistance results [ 1 11. 
In Table 1, the results for gatifloxacin indexed by 
organism genus or species are summarized. The 
gatifloxacin MIC50 results for all strains tested ranged 
from 0.25 to 4mg/L. The most elevated MICs for 
gatifloxacin were documented for the Bacteroides spp. 
other than Bacteroides fragilis (MIC90, 32 mg/L), 
Prevotella spp. (MI%, 8 mg/L) and Peptostreptococcus 
spp. (MI(&, >32 mg/L). Trovafloxacin was more 
potent (4-8-fold) than gatifloxacin against some strains. 
Metronidazole was the most active agent tested 
according to spectrum of activity analysis (resistant at 
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Table 1 
anaerobic bacteria 
Antimicrobial activity of gatifloxacin compared to three other antimicrobial agents tested against 202 strains of 
MIC (mg/L) 
Organism (no. tested) Method Antimicrobial agent 50% 90% Range 
Bacteroides fragilis (103) Agar dilution 
Etest 
Bacferoides spp.. other (37)” Agar dilution 
Etest 
Clostridium spp. 
Fusobucterium spp. (10) 
Preuotella spp. (10)’ 
Agar dilution 
Etest 
Agar dilution 
Etest 
Agar dilution 
Etest 
Peptostreptococcus spp. (10) Agar dilution 
Etest 
Propionibucterium acnes (14) Agar dilution 
Etest 
Other species (8)d Agar dllution 
Etest 
Gatifloxacin 
Gatifloxacin 
Clindamy cin 
Metronidazole 
Trodoxacin 
Gatifloxacin 
Gatifloxacin 
Clindamy cin 
Metronidazole 
Trovafloxacin 
Gatifloxacin 
Gatifloxacin 
Clindamy cin 
Metronidazole 
Trovafloxacin 
Gatifloxacin 
Gatifloxacin 
Clindamycin 
Metronidazole 
Trovafloxacin 
Gatifloxacin 
Gatifloxacin 
Clindamycin 
Metronidazole 
Trovafloxacin 
Gatifloxacin 
Gatifloxacin 
Clindamycin 
Metronidazole 
Trovdoxacin 
Gatifloxacin 
Gatifloxacin 
Chdamycin 
Metronidazole 
Trovafloxacin 
Gatifloxacin 
Gatifloxacin 
Clindamycin 
Metronidazole 
Trovafloxacin 
1 
1 
2 
0.75 
0.19 
2 
2 
4 
1 
0.38 
1 
0.5 
4 
2 
0.19 
0.25 
0.125 
0.047 
0.023 
0.19 
4 
3 
0.023 
0.75 
1.5 
2 
0.75 
0.094 
0.19 
0.25 
0.5 
0.19 
0.094 
0.38 
0.25 
0.19 
0.064 
1 
0.25 
> 32 
4 
6 
>256 
2 
1.5 
32 
> 32 
>256 
3 
2 
4 
3 
16 
2 
1.5 
0.5 
0.19 
0.094 
0.094 
0.25 
4 
8 
0.047 
3 
3 
>32 
> 32 
0.5 
1 
> 32 
0.5 
0.19 
0.25 
0.5 
>32 
- 
- 
- 
- 
- 
0.25 to >32 
0.125 to >32 
50.016 to >256 
0.094 to 732 
0.032 to >32 
0.25 to >32 
0.5 to >32 
0.032 to >256 
0.04774 
0.094 to >32 
0.06-4 
0.047-4 
0.75 to >256 
0.19-3 
0.032-3 
0.12-0.5 
0.047-0.25 
10.016-2 
S0.0163 
0.094-0.38 
1-4 
0.38 to >32 
0.125 to >32 
0.5 to >32 
10.016-4 
0.25 to >32 
0.064 to >32 
0.023 to >256 
0.023 to >32 
0.023 to >32 
0.5 
0.19-0.25 
0.047-0.5 
0.25-0.5 
>32 
0.25-8 
0.094-6 
0.032-3 
0.125-12 
0.094 to >32 
’Includes Bacteroides m e  (four strains), Bucteroides distasonis (three strains), Bacteroides eggerthii (one strain), Bucteroides merdue (one strain), 
Barteroides ovatus (six t rains) ,  Bacteroides thetaiotaominon (1 1 strains), Bacteroides un$ormis (five strains), and Bacteroides uulgatus (six strains). 
bIncludes Clostridium butyricum (two strains), C. dijicile (one strain), C. clostridiofrme (one strain), C. pe+wgens (four strains), C. sporogenes 
(one strain), and C. histolytinrm (one strain). 
‘Includes Prwofella biuia (five strains), Revofella oris (one strain), Preuotella melaninogenicus (one strain), and Preuotella spp. (three strains). 
dIncludes Bijdobacterium spp. (two strains), Eubucterium spp. (two strains), and Killonella spp. (four strains). 
2 3 2  mg/L), with only four (2.1%) resistant strains 
among all anaerobes tested other than Propionibacterium 
acner. Clindamycin was the least effective (MIC90s 
0.047 to >256 mg/L) drug tested against these con- 
temporary isolates. 
Table 2 lists the comparison of MICs obtained by 
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Table 2 Comparison of Etest and reference agar dilution results for gatifloxacin tested against 202 strains of anaerobic 
bacteria 
Etest MIC/Agar MIC ratio (?h) 
2 + 2  +1.5 +1.0 +0.5 0 -0.5 -1.0 -1.5 -9 
-~ ~ ~ 
4 Ob 18" 22" 40" 39" 43" 32b 4 
(2.0) (0.0) (8.9) (10.9) (19.8) (19.3) (21.3) (15.8) (2.0) 
"Percentage? 1 log  dilution=80.2%. 
bPercentage? 1.5 log2 dilution=96.0%. 
the Etest and reference agar dilution methods [9]. 
Using the Etest/agar dilution MIC ratios as a measure 
of similarity, acceptable correlation was obtained (80.2 
and 96.0% at +1 log2 and k l . 5  log2 dilution steps, 
respectively). Only 1% ofEtest results were beyond +2  
log2 dilutions as compared to the reference test MIC. 
A slight trend towards a lower gatifloxacin MIC with 
the Etest was observed. 
Although gatifloxacin has demonstrated a wide 
spectrum against aerobic pathogens [4-71, a more 
limited activity was observed against anaerobic species. 
For the Bacteroides fragilis strains (103 organisms), the 
gatifloxacin and trovafloxacin MIC90 results were 
4 mg/L and 1.5 mg/L, respectively. This agrees with 
the reports from Japan [4,5] and Germany [6], where 
the gatifloxacin MIC90 ranged from 1 to 3.13 mg/L. 
Several investigators have reported that gatifloxacin 
activity was equal to that of trovafloxacin or spar- 
floxacin [4-71. Other anaerobes or related fastidious 
facultative anaerobes reported as susceptible to gati- 
floxacin were Mobiluncus spp. (MI&, 0.20 mg/L) and 
Gardenerella vaginalis (MIC90, 1.56 mg/L) [2]. 
Clearly, the majority of anaerobes tested in 
this study were inhibited by 12mg/L (76.2%) and 
1 4  mg/L (86.6%) of gatifloxacin, and these results 
would be very similar to those for trovafloxacin if 
pharmacodynamic differences between the two newer 
fluoroquinolones were considered p]. The gatifloxacin 
C,, for a 600-mg dose was 5.41 mg/L, with a 7-8-h 
serum elimination half-life, showing potential thera- 
peutic application to infections caused by anaerobic 
pathogens [S]. When gatifloxacin is used for these 
organisms, its activity can be followed conveniently by 
the Etest stable gradient method. Gatifloxacin activity 
against strict anaerobic bacteria requires that pharmaco- 
kinetic features be considered, to achieve adequate drug 
concentrations for potential therapy. 
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